These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16291879)

  • 21. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Rev Neurother; 2009 Jul; 9(7):1073-85. PubMed ID: 19589055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid cognitive decline in Alzheimer's disease: a literature review.
    Sona A; Ellis KA; Ames D
    Int Rev Psychiatry; 2013 Dec; 25(6):650-8. PubMed ID: 24423219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Behavioural and psychological symptoms in dementia in Alzheimer's disease].
    Benoit M; Robert P
    Rev Prat; 2005 Nov; 55(17):1895-901. PubMed ID: 16396230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Contribution of omega-3 fatty acids for memory and cognitive function].
    Waitzberg DL; Garla P
    Nutr Hosp; 2014 Sep; 30(3):467-77. PubMed ID: 25238820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in pharmacotherapy for decline of memory and cognition in patients with Alzheimer's disease.
    Kumar V; Goldstein MZ; Doraiswamy PM
    Psychiatr Serv; 1996 Mar; 47(3):249-53. PubMed ID: 8820547
    [No Abstract]   [Full Text] [Related]  

  • 26. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sleep and cognition in people with Alzheimer's disease.
    Cole CS; Richards KC
    Issues Ment Health Nurs; 2005; 26(7):687-98. PubMed ID: 16126646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
    Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
    J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hallucinations, cognitive decline, and death in Alzheimer's disease.
    Wilson RS; Tang Y; Aggarwal NT; Gilley DW; McCann JJ; Bienias JL; Evans DA
    Neuroepidemiology; 2006; 26(2):68-75. PubMed ID: 16352909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
    Visser PJ; Scheltens P; Verhey FR
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1348-54. PubMed ID: 16170074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.
    Livingston G; Walker AE; Katona CL; Cooper C
    J Neurol Neurosurg Psychiatry; 2007 Jan; 78(1):25-9. PubMed ID: 16801350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives of Alzheimer's disease treatments.
    Davis JB; Bountra C; Richardson J
    Handb Clin Neurol; 2008; 89():273-90. PubMed ID: 18631752
    [No Abstract]   [Full Text] [Related]  

  • 33. Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST).
    Scutt P; Blackburn D; Krishnan K; Ballard C; Burns A; Ford GA; Mant J; Passmore P; Pocock S; Reckless J; Sprigg N; Stewart R; Wardlaw JM; Bath PM
    Trials; 2015 Nov; 16():509. PubMed ID: 26545986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progressive and unconventional pharmacotherapeutic approaches to Alzheimer's disease therapy.
    Maudsley S; Chadwick W
    Curr Alzheimer Res; 2012 Jan; 9(1):1-4. PubMed ID: 22329648
    [No Abstract]   [Full Text] [Related]  

  • 35. Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease.
    de Oliveira FF; Bertolucci PH; Chen ES; Smith MC
    J Alzheimers Dis; 2014; 42 Suppl 3():S321-4. PubMed ID: 24577465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.
    Lu PH; Masterman DA; Mulnard R; Cotman C; Miller B; Yaffe K; Reback E; Porter V; Swerdloff R; Cummings JL
    Arch Neurol; 2006 Feb; 63(2):177-85. PubMed ID: 16344336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hearing impairment and cognitive function in Alzheimer's disease.
    Weinstein BE; Amsel L
    J Am Geriatr Soc; 1987 Mar; 35(3):273-5. PubMed ID: 3819271
    [No Abstract]   [Full Text] [Related]  

  • 38. Psychopharmacology and Alzheimer's disease.
    Serby M
    J Adv Med Surg Nurs; 1989 Mar; 1(2):32-9. PubMed ID: 2664071
    [No Abstract]   [Full Text] [Related]  

  • 39. Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.
    Velayudhan L; Proitsi P; Westman E; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Hodges A; Powell J; Lovestone S; Simmons A;
    J Alzheimers Dis; 2013; 33(3):755-66. PubMed ID: 23047370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.